Testing and tweaking custom drug rules (B425)

[Flyndaran]

Weak patents mean weak incentive to do the initial research. Not a good thing in my book.
I hope that the future of medication will be more about individual's unique biochemistry and less about more haphazard trials and statistical analysis of what and how bad it goes wrong.
"Hey, we can tell that someone with your biochemistry is nearly immune to opiates, but can safely take X to deal with your post operative pain."
I wished that happened to me a few years back.

[vicky_molokh]

Originally Posted by Flyndaran

Weak patents mean weak incentive to do the initial research. Not a good thing in my book.
I hope that the future of medication will be more about individual's unique biochemistry and less about more haphazard trials and statistical analysis of what and how bad it goes wrong.
"Hey, we can tell that someone with your biochemistry is nearly immune to opiates, but can safely take X to deal with your post operative pain."
I wished that happened to me a few years back.

I'd rather not move this thread into the territory of infosocialism vs. infocapitalism debate. Suffice it to say that scientists have done a fair share of research not for patents on Homeline Terra, so hypothetical settings can have differing levels of patent strength, with different outcomes (because outcomes depend on more outcomes than one).

But regarding customisation of drugs and optimisation of recipes for an individual's biochemistry: this is the sort of service that the friendly local apothecary definitely provides in my current setting.